Overview
Clarithromycin is a semi-synthetic macrolide antibiotic, structurally related to erythromycin but engineered to offer improved acid stability, better oral absorption, and a broader spectrum of activity. It is widely used to treat a variety of mild to moderate bacterial infections, including pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, and pneumonia. Notably, clarithromycin is a critical component of the triple therapy regimen used to eradicate Helicobacter pylori in patients with peptic ulcer disease. It is also utilized for the prevention and treatment of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.

Mechanism of Action
Like other macrolides, clarithromycin acts as a bacteriostatic agent by binding to the 50S ribosomal subunit of susceptible bacteria. This action suppresses protein synthesis by inhibiting the translocation of aminoacyl transfer-RNA and preventing peptide chain elongation. Its active metabolite, 14-OH clarithromycin, also possesses significant antibacterial activity, acting synergistically with the parent compound against certain pathogens like Haemophilus influenzae.

Dosage and Administration
For adults, the typical oral dosage is 250 mg to 500 mg every 12 hours for 7 to 14 days, depending on the severity and type of infection. For the eradication of H. pylori, it is usually given as 500 mg twice daily in combination with amoxicillin and a proton pump inhibitor for 10 to 14 days. Pediatric dosing is generally 7.5 mg/kg every 12 hours. Immediate-release tablets and oral suspensions can be taken with or without food, but extended-release tablets must be taken with food.

Side Effects and Risks
Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, vomiting, and abdominal pain. A distinctive side effect of clarithromycin is a noticeable alteration in taste (dysgeusia), often described as a metallic or bitter taste in the mouth. Like azithromycin, clarithromycin carries a risk of QT interval prolongation and cardiovascular events. Furthermore, it is a strong inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system, leading to numerous and potentially severe drug-drug interactions (e.g., with statins, calcium channel blockers, and certain anticoagulants).

Contraindications
Clarithromycin is contraindicated in patients with a known hypersensitivity to macrolide antibiotics. Due to severe drug interactions, it must not be co-administered with drugs like astemizole, cisapride, pimozide, terfenadine, ergotamine, or statins that are extensively metabolized by CYP3A4 (like simvastatin or lovastatin). It is also contraindicated in patients with a history of QT prolongation or ventricular cardiac arrhythmia, and in patients with severe hepatic failure in combination with renal impairment.

Pregnancy and Lactation
Clarithromycin is generally not recommended during pregnancy unless no alternative therapy is appropriate. Animal studies have shown adverse effects on fetal development, though human data is limited. It is excreted in human breast milk. Caution should be exercised when administering clarithromycin to a nursing woman, and the infant should be monitored for potential adverse effects.